This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shenai, J. P.
Right arrow Articles by Chytil, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shenai, J. P.
Right arrow Articles by Chytil, F.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 106 No. 3 September 2000, pp. 547-553

Vitamin A Status and Postnatal Dexamethasone Treatment in Bronchopulmonary Dysplasia

Received Jun 29, 1999; accepted Dec 23, 1999.

Jayant P. Shenai*, Beverly G. MellenDagger , and Frank Chytil§

From the Departments of * Pediatrics, Dagger  Preventive Medicine, and § Biochemistry, Vanderbilt University, Nashville, Tennessee.

Objective.  Vitamin A (retinol) plays an important role in epithelial regeneration during recovery from lung injury in bronchopulmonary dysplasia (BPD). Dexamethasone is used in the postnatal treatment of very low birth weight (VLBW) neonates with BPD. To test the hypothesis that the vitamin A status is critical for the beneficial pulmonary response to dexamethasone, we performed a prospective cohort study in which we characterized the changes in plasma concentrations of vitamin A and retinol-binding protein (RBP) in response to dexamethasone, and correlated these changes with the pulmonary outcome.

Methods.  VLBW neonates (birth weight <1350 g, gestational age <31 weeks, postnatal age >10 days), who had presumptive diagnosis of severe BPD and need for high ventilatory support (fraction of inspired oxygen >= .6, mean airway pressure >= 7 cm H2O), were treated with a seven-day course of dexamethasone (.5 mg/kg/d × 2 days, .25 mg/kg/d × 2 days, .1 mg/kg/d × 3 days). Plasma concentrations of vitamin A and RBP were determined sequentially at baseline, and during and after dexamethasone treatment. Pulmonary response to dexamethasone was graded daily using a composite ventilation score. The changes in plasma vitamin A and RBP concentrations were compared between infants with a positive (beneficial) pulmonary response to dexamethasone and those with a negative response.

Results.  Among 23 infants studied, 13 showed a positive pulmonary response to dexamethasone, as indicated by successful weaning from supplemental oxygen and mechanical ventilation, whereas 10 showed a negative response. A significant, yet short-term, increase in plasma concentrations of both vitamin A and RBP was observed in most infants treated with dexamethasone. The plasma vitamin A and RBP responses to dexamethasone tended to be higher in infants with a positive pulmonary response than in those with a negative response. Accounting for gender, a vitamin A response with each 10.0 µg/dL increment in plasma vitamin A concentration was associated with a 60% increase in the odds favoring a positive pulmonary response to dexamethasone.

Conclusion.  Postnatal dexamethasone treatment in VLBW neonates with BPD induces a significant, yet short-term, increase in plasma concentrations of both vitamin A and RBP. This increase probably results from endogenous mobilization of vitamin A from the liver. Our data suggest that the beneficial pulmonary response to dexamethasone in infants with BPD is influenced, at least in part, by the vitamin A status, and that gender plays a role in this response.vitamin A, dexamethasone, bronchopulmonary dysplasia. .


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
H Mactier and L T Weaver
Vitamin A and preterm infants: what we know, what we don't know, and what we need to know
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2005; 90(2): F103 - F108.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L.-Y. L. Chang, M. Subramaniam, B. A. Yoder, B. J. Day, M. C. Ellison, M. E. Sunday, and J. D. Crapo
A Catalytic Antioxidant Attenuates Alveolar Structural Remodeling in Bronchopulmonary Dysplasia
Am. J. Respir. Crit. Care Med., January 1, 2003; 167(1): 57 - 64.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. A. Atkinson
Special Nutritional Needs of Infants for Prevention of and Recovery from Bronchopulmonary Dysplasia
J. Nutr., March 1, 2001; 131(3): 942S - 946.
[Abstract] [Full Text]